Pelthos Therapeutics Inc. (CHRO)

Overview

Channel Therapeutics Corporation, formerly known as Chromocell Therapeutics Corporation, is a clinical-stage biotechnology company focused on the development and commercialization of novel therapeutics for pain relief. With a keen focus on the sodium ion-channel known as NaV1.7, among others in the NaV family, they aim to invent treatments that can alleviate various types of pain. Initially founded in 2002 and based in Freehold, New Jersey, Channel Therapeutics has transitioned its name in November 2024 to better reflect its dedicated mission towards pioneering advancements in the realm of pain management. By concentrating on these specific channels, the company endeavors to bring groundbreaking pain relief solutions to patients worldwide.

Products and Services

• CC8464 - Phase 2a Clinical Trials
  

  The forefront of Channel Therapeutics Corporation's product lineup is CC8464, which is currently undergoing Phase 2a clinical trials. CC8464 represents a significant advancement in the treatment of erythromelalgia, a rare, debilitating condition characterized by severe burning pain and redness primarily in the extremities. Apart from its application in erythromelalgia, CC8464 is also being explored for its potential in addressing a broader spectrum of neuropathic pain as well as in the management of both acute and chronic eye pain. This promising therapeutic compound demonstrates Channel Therapeutics' commitment to targeting the NaV1.7 channel among others, aiming to unlock new, effective treatments for patients suffering from various pain conditions.